drugset / Trial / NCT05128344

A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

NCT05128344

Phase 3 Withdrawn Amzell
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the efficacy of AMZ002 compared to Vigabatrin in participants with newly diagnosed infantile spasms (IS).

Timeline

Start
2023-04
Primary completion
2025-06
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject AMZ002 Unknown 0.5 mg/ml Other
Comparator Vigabatrin Small molecule Oral

Indications